BIOLIFE SOLUTIONS INC (BLFS) competitors & alternatives
Health Care · NASDAQ
BIOLIFE SOLUTIONS INC (BLFS)'s top competitors and alternatives — its most similar public companies — include Thermo Fisher Scientific (TMO), Danaher Corporation (DHR), AZENTA INC (AZTA), CRYOPORT INC (CYRX), CRISPR THERAPEUTICS AG (CRSP), CENTURY THERAPEUTICS INC (IPSC), ABEONA THERAPEUTICS INC (ABEO), VERICEL CORP (VCEL), PRECIGEN INC (PGEN), SANA BIOTECHNOLOGY INC (SANA), MaxCyte, Inc. (MXCT) and Vertex Pharmaceuticals (VRTX). These are BIOLIFE SOLUTIONS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top BLFS competitors & alternatives
-
Thermo Fisher ScientificTMOHealth Care
Thermo Fisher Scientific is a leading global provider of mission-critical laboratory equipment, analytical instrumentation, and scientific services for…
$526.46 (as of 2026-07-22) · market cap $194.1B
-
Danaher CorporationDHRHealth Care
Danaher is a diversified conglomerate providing scientific instruments, diagnostics, and industrial solutions across life sciences, environmental monitoring,…
$179.14 (as of 2026-07-22) · market cap $125.9B
-
AZENTA INCAZTAHealth Care
Azenta is a provider of life sciences solutions focused on automated sample management and genomic services for research and clinical development.
$27.16 (as of 2026-07-22) · market cap $1.2B
-
CRYOPORT INCCYRXHealth Care
Cryoport is the leading provider of end-to-end temperature-controlled supply chain solutions specifically built for cell and gene therapies, from preclinical…
$16.42 (as of 2026-07-22) · market cap $838M
-
CRISPR THERAPEUTICS AGCRSPHealth Care
CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and…
$47.24 (as of 2026-07-22) · market cap $4.6B
-
CENTURY THERAPEUTICS INCIPSCHealth Care
Century Therapeutics is an innovative biotechnology firm developing off-the-shelf, gene-edited iPSC-derived cell therapies to cure cancer and autoimmune…
$2.15 (as of 2026-07-22) · market cap $388M
-
ABEONA THERAPEUTICS INCABEOHealth Care
Abeona is a commercial-stage biopharmaceutical company that just received FDA approval for ZEVASKYN®, the first and only autologous cell-based gene therapy for…
$6.42 (as of 2026-07-22) · market cap $374M
-
VERICEL CORPVCELHealth Care
Vericel is a leader in advanced autologous cell therapies for sports medicine and severe burn care, with FDA-approved products MACI for cartilage repair and…
$44.56 (as of 2026-07-22) · market cap $2.4B
-
PRECIGEN INCPGENHealth Care
Gene therapy precision medicine company with FDA-approved adenoviral immunotherapy for HPV-driven respiratory disease and a development pipeline of CAR-T and…
$5.32 (as of 2026-07-22) · market cap $1.9B
-
SANA BIOTECHNOLOGY INCSANAHealth Care
Sana Biotechnology is developing ex vivo and in vivo engineered cell therapy platforms to transform the treatment of diseases like type 1 diabetes, oncology,…
$3.12 (as of 2026-07-22) · market cap $868M
-
MaxCyte, Inc.MXCTHealth Care
MaxCyte enables cell therapy development through proprietary electroporation technology that delivers molecules into cells for engineering next-generation…
$1.14 (as of 2026-07-22) · market cap $125M
-
Vertex PharmaceuticalsVRTXHealth Care
Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and…
$472.57 (as of 2026-07-22) · market cap $121.4B
Not quite? Describe exactly what you want →
Peers are BIOLIFE SOLUTIONS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: BIOLIFE SOLUTIONS INC (BLFS).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.